Cargando…
Novel Knowledge about Molecular Mechanisms of Heparin-Induced Thrombocytopenia Type II and Treatment Targets
Heparin-induced thrombocytopenia type II (HIT II), as stated in the literature, occurs in about 3% of all patients and in 0.1–5% of surgical patients. Thrombosis develops in 20–64% of patients with HIT. The mortality rate in HIT II has not decreased using non-heparin treatment with anticoagulants su...
Autores principales: | Mongirdienė, Aušra, Liuizė, Agnė, Kašauskas, Artūras |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179321/ https://www.ncbi.nlm.nih.gov/pubmed/37175923 http://dx.doi.org/10.3390/ijms24098217 |
Ejemplares similares
-
The Effect of Oxidant Hypochlorous Acid on Platelet Aggregation and Dityrosine Concentration in Chronic Heart Failure Patients and Healthy Controls
por: Mongirdienė, Aušra, et al.
Publicado: (2019) -
Relationship between Oxidative Stress and Left Ventricle Markers in Patients with Chronic Heart Failure
por: Mongirdienė, Aušra, et al.
Publicado: (2023) -
Heparin: Type II thrombocytopenia: case report
Publicado: (2022) -
Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II
por: Grouzi, Elisavet
Publicado: (2014) -
Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
por: Honore, Patrick M., et al.
Publicado: (2016)